Targeting c-rel o-glcnacylation and uses thereof
AssigneeCalifornia Institute of Technology
InventorsParameswaran Ramakrishnan, David Baltimore
Life of this patent
Estimating the term…
Abstract
Serine 350 has been identified as the site of O-GlycNAcylation of c-Rel. Methods are provided for identifying compositions capable of blocking c-Rel activation. The methods generally involve identifying compounds that inhibit O-GlcNAcylation of c-Rel at the serine 350 residue, thereby preventing c-Rel activation and production of c-Rel-dependent cytokines.
Claims26
A method of identifying a composition that can inhibit O-GlcNAcylation of c-Rel, comprising:
- providing one or more compositions to be tested;
- testing the one or more compositions for their ability to inhibit the attachment of N-acetylglucosamine to serine 350 of c-Rel;
- and
- identifying a composition that inhibits the attachment of N-acetylglucosamine to serine 350 of c-Rel as an inhibitor of O-GlcNAcylation of c-Rel.
A method of identifying a composition that inhibits expression of c-Rel-dependent NF-κB-related cytokines, the method comprising:
- a) providing one or more test compositions;
- b) identifying a test composition that inhibits O-GlcNAcylation of c-Rel;
- and
- c) testing the test composition identified in b) for its ability to inhibit expression of c-Rel-dependent NF-κB-related cytokines in T cells.
A method of inhibiting expression c-Rel-dependent genes, the method comprising:
- administering an inhibitor of c-Rel O-GlcNAcylation to a cell;
- and
- monitoring at least one marker of c-Rel-dependent gene expression.
Dependencies are inferred from the claim text.